Publications by authors named "Utsunomiya A"

Here, we report a rare case of relapsed adult T-cell leukemia-lymphoma (ATL) with evidence of clonal relapse 26 years after initial diagnosis. The patient had been diagnosed with an aggressive form of lymphoma-type ATL 26 years prior and did not receive further ATL treatment for approximately 26 years after achieving complete remission. We used nested PCR to identify the amplification of ATL clone-specific accumulation sites in DNA from hematoxylin and eosin-stained specimens from the patient.

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitors (ICIs) play a central role in cancer immunotherapy. However, the occurrence of immune-related adverse events, especially ICI-induced interstitial lung disease (ICI-ILD), is life-threatening and affects the effectiveness of ICI treatment. This study aimed to explore potential drugs to mitigate ICI-ILD occurrence using data from the Japanese Adverse Drug Event Report (JADER) and the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS [JAPIC AERS]).

View Article and Find Full Text PDF

Adult T-cell leukemia/lymphoma (ATLL) is a refractory blood cancer with severe immunodeficiency resulting from retroviral infection. ATLL develops in only 5 % of HTLV-1-infected individuals, but the entire mechanism of ATLL progression remains unknown. Since recent studies have reported that the gut microbiome influences the progression of various diseases, we hypothesized that ATLL is also related to the gut microbiome and aimed to investigate this relationship.

View Article and Find Full Text PDF
Article Synopsis
  • Residual feed intake (RFI) is a key measure of feed efficiency considered in dairy cattle breeding, focusing on genetic parameters associated with traits like dry-matter intake (DMI), body weight (BW), and energy-corrected milk (ECM).
  • The study analyzed RFI data from 2,538 lactating Holstein cows, leveraging 61,283 genetic markers to estimate heritability and genetic correlations between heifers and cows.
  • Findings revealed moderate heritability estimates for RFI (0.43), DMI (0.44), ECM (0.40), and BW (0.46), alongside reliability metrics indicating 44% for the training population and 30% for the prediction population
View Article and Find Full Text PDF

Here, we investigated the clinical significance of NOTCH1 and FBXW7 alterations for adult T-cell leukemia/lymphoma (ATLL) treatment outcomes. NOTCH1 alterations were identified in 37 (14.4%) of 257 patients, of which 33 were single nucleotide variants/insertion-deletions in the PEST domain, and 7 were in the heterodimerization or LIN-12/Notch repeats domains.

View Article and Find Full Text PDF
Article Synopsis
  • Researchers are testing valemetostat, an EZH2 and EZH1 inhibitor, for safety and effectiveness in patients with relapsed or refractory non-Hodgkin lymphoma, due to limited treatment options and poor outcomes.
  • The study involved 90 participants from 19 hospitals across Japan and the USA, who received varying doses of valemetostat in a phase 1 clinical trial to find the right dosage and assess its anti-tumor effects.
  • Initial findings will help determine the most effective dosages and provide insights into the drug's safety profile, with a majority of patients having peripheral T-cell lymphoma.
View Article and Find Full Text PDF
Article Synopsis
  • - HTLV-1 can quickly transform CD4+ T cells in a lab setting, but most infected people remain asymptomatic, indicating a balance between the virus and the host's immune response.
  • - The study found a variant in the HTLV-1 Tax301-309 viral antigen in individuals with a specific HLA-A24 type, which affected the detection of anti-Tax cytotoxic T cells (CTLs).
  • - More than half of the T-cell receptors (TCRs) from these anti-Tax CTLs failed to recognize the mismatched Tax301-309 peptides, underlining the need for precise matching of viral antigens in T-cell therapy for adult T-cell leukemia (ATL).
View Article and Find Full Text PDF

This study aimed to investigate the recovery of physical function, muscle mass, and quality of life (QOL) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients 1 year after the procedure. A total of 71 patients who underwent allo-HSCT at our institution between February 2010 and June 2020, for whom a physical therapy assessment could be performed before allo-HSCT, at discharge, and 1 year after the procedure, were included. Exercise therapy during hospitalization was provided individually by a physical therapist, and exercise was self-administered after discharge.

View Article and Find Full Text PDF
Article Synopsis
  • Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is the main treatment for adult T-cell leukemia/lymphoma (ATL) and is influenced by individual human leukocyte antigens (HLAs).
  • A study analyzed data from 829 ATL patients who received transplants, identifying HLA-B62 as linked to lower mortality risk and HLA-B60 with higher mortality risk after transplantation.
  • The findings suggest that specific HLAs can help predict treatment outcomes for ATL patients undergoing allo-HSCT, with potential implications for patient management.
View Article and Find Full Text PDF

Aortic sarcomas are extremely rare. Sarcomas associated with aortic graft replacement are even rarer; only 17 cases have been examined through immunohistochemical staining to date, most of which were either angiosarcomas or intimal sarcomas. Here, we report the case of an 88-year-old man with an undifferentiated pleomorphic sarcoma (UPS) that developed after aortic graft replacement and was diagnosed through postmortem autopsy.

View Article and Find Full Text PDF

Background: Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular injury and inflammation, followed by excessive fibrosis of the skin and other internal organs, including the lungs. CX3CL1 (fractalkine), a chemokine expressed on endothelial cells, supports the migration of macrophages and T cells that express its specific receptor CX3CR1 into targeted tissues. We previously reported that anti-CX3CL1 monoclonal antibody (mAb) treatment significantly inhibited transforming growth factor (TGF)-β1-induced expression of type I collagen and fibronectin 1 in human dermal fibroblasts.

View Article and Find Full Text PDF

Chronic lymphocytic leukemia (CLL) is rare in Japan. We conducted the nationwide, prospective observational study CLLRSG-01 to clarify the current state of CLL in Japan and to make accurate international comparisons by preparing naturally air-dried smears like those used in other countries. Of the 201 untreated patients enrolled and evaluated, 119 were diagnosed with CLL and 82 with non-CLL mature B-cell neoplasms, based on the WHO classification.

View Article and Find Full Text PDF

Here we report the largest Asian genome-wide association study (GWAS) for systemic sclerosis performed to date, based on data from Japanese subjects and comprising of 1428 cases and 112,599 controls. The lead SNP is in the FCGR/FCRL region, which shows a penetrating association in the Asian population, while a complete linkage disequilibrium SNP, rs10917688, is found in a cis-regulatory element for IRF8. IRF8 is also a significant locus in European GWAS for systemic sclerosis, but rs10917688 only shows an association in the presence of the risk allele of IRF8 in the Japanese population.

View Article and Find Full Text PDF

Background: Whether human T-lymphotropic virus type 1 (HTLV-1) carriers can develop sufficient humoral immunity after coronavirus disease 2019 (COVID-19) vaccination is unknown.

Methods: To investigate humoral immunity after COVID-19 vaccination in HTLV-1 carriers, a multicenter, prospective observational cohort study was conducted at five institutions in southwestern Japan, an endemic area for HTLV-1. HTLV-1 carriers and HTLV-1-negative controls were enrolled for this study from January to December 2022.

View Article and Find Full Text PDF

Background: Human T-cell leukemia virus type I (HTLV-1) is a retrovirus known to cause adult T-cell leukemia/lymphoma (ATL). There are few reports on hematopoietic stem cell transplantation (HSCT) for HTLV-1 carriers with diseases other than ATL.

Methods: A total of 25,839 patients (24,399 adults and 1440 children) with pre-transplant HTLV-1 serostatus information recorded in the Japanese National Survey Database who had undergone their first HSCT were analyzed.

View Article and Find Full Text PDF

Naldemedine is structurally designed to prevent passage across the blood-brain barrier (BBB), resulting in the attenuation of opioid-induced constipation without interfering with the analgesic effects of opioids. However, the influence of brain metastasis (BM), as one indicator of BBB disruption, on the analgesic effects of opioids in patients treated with naldemedine remains unclear. To examine whether the analgesic effects of opioids following naldemedine treatment are lower in patients with BM than in those without BM, we surveyed inpatients with lung and breast cancers treated with naldemedine at Fujita Health University Hospital between April 2017 and March 2022.

View Article and Find Full Text PDF
Article Synopsis
  • The World Health Organization estimates that 5-10 million people are infected with HTLV-1, but this number could be low due to limited data.
  • Reliable data exists for only about 1.5 billion people worldwide, leaving many infections potentially undetected.
  • The study evaluates a new rapid test, Espline HTLV-I/II, which could enhance our ability to quickly and easily identify HTLV-1 infections without needing expensive lab equipment.
View Article and Find Full Text PDF

Human T-cell leukemia virus type 1 (HTLV-1) establishes chronic infection in humans and induces a T-cell malignancy called adult T-cell leukemia-lymphoma (ATL) and several inflammatory diseases such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Persistent HTLV-1 infection is established under the pressure of host immunity, and therefore the immune response against HTLV-1 is thought to reflect the status of the disease it causes. Indeed, it is known that cellular immunity against viral antigens is suppressed in ATL patients compared to HAM/TSP patients.

View Article and Find Full Text PDF

Background: Systemic sclerosis (SSc) is a connective tissue disease that is characterized by fibrosis in the skin and internal organs, such as the lungs. Activated differentiation of progenitor cells, which are mainly resident fibroblasts, into myofibroblasts is considered a key mechanism underlying the overproduction of extracellular matrix and the resultant tissue fibrosis in SSc. Calpains are members of the Ca-dependent cysteine protease family, whose enzymatic activities participate in signal transduction and tissue remodeling, potentially contributing to fibrosis in various organs.

View Article and Find Full Text PDF

Background: No assessment tool for predicting ventilator withdrawal success is currently available in Japan. Thus, an accessible and valid assessment tool to address this issue is needed. The Burns Wean Assessment Program (BWAP) has been validated as a reliable predictor of ventilator withdrawal outcomes.

View Article and Find Full Text PDF
Article Synopsis
  • Essential thrombocythemia (ET) cases can sometimes be triple-negative (TN), meaning they don't have the common JAK2, CALR, or MPL mutations, accounting for 10%-20% of ET cases.
  • A study of 119 ET patients found that 20 (16.8%) were triple-negative, often presenting with younger ages and lower white blood cell counts and lactate dehydrogenase levels.
  • The researchers identified several novel driver mutations in these TN cases, including some germline mutations linked to hereditary thrombocytosis, suggesting a need for further exploration of genetic factors in TN ET for better clinical management.
View Article and Find Full Text PDF

The prognosis of aggressive adult T-cell leukemia/lymphoma (ATL) is poor, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment. In order to identify favorable prognostic patients after intensive chemotherapy, and who therefore might not require upfront allo-HSCT, we aimed to improve risk stratification of aggressive ATL patients aged <70 years. The clinical risk factors and genetic mutations were incorporated into risk modeling for overall survival (OS).

View Article and Find Full Text PDF

Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell malignancy caused by human T-cell leukemia virus type-I (HTLV-1). This study investigated whether the number of newly diagnosed patients with ATL is decreasing in the background of a declining number of individuals infected by HTLV-1 in Kagoshima, Japan, one of the most endemic areas of HTLV-1 in the world. We retrospectively analyzed the number of newly diagnosed patients with ATL between January 2001 and December 2021 in three major hospitals.

View Article and Find Full Text PDF